Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs

Yaoxue Xuebao

Volumn 40, Issue 10, 2005, Pages 912-915

  Li, Qiang ^b   Huang, Hai Hua ^a   Dong, Yu ^a   Zhong, Da Fang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Cytochrome P450; Hydroxylation metabolism; Imrecoxib; Liquid chromatography multistage mass spectrometry; Total normalized rate

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; IMRECOXIB; PYRROLE DERIVATIVE; SULFIDE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; ELECTROSPRAY MASS SPECTROMETRY; HYDROXYLATION; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HYDROXYLATION; PYRROLES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFIDES;

EID: 28444433800     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Bai AP, Guo ZR, Hu WH, et al. Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3, 4-diaryl-3-pyrrolin-2- ones [J]. Chin Chem Lett, 2001,12(9):775-778.
2. Slaughter D, Takenaga N, Lu P, et al. Metabolism of rofecoxib in vitro using human liver subcellular fractions [J]. Drug Metab Dispos, 2003,31(11):1398-1408.
3. Ibrahim A, Karim A, Feldman J, et al. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam [J]. Anesth Analg, 2002,95(3):667-673.
4. Kassahun K, McIntosh IS, Shou M, et al. Role of human liver cytochrome P450 3 A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor [J]. Drug Metab Dispos, 2001,29(6):813-820.
5. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes [J]. Biochem Pharmacol, 1999,57 (5):465-480.
6. The Food and Drug Administration. Drug metabolism/drug interaction studies in the drug development process: studies in vitro [S]. 1997.